{"analyses":[{"ciLowerLimit":"0.70","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.05","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1343","paramType":"Hazard Ratio (HR)","paramValue":"0.86","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.70","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.05","groupDescription":"Unstratified Analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1285","paramType":"Hazard Ratio (HR)","paramValue":"0.86","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.36","upperLimit":"6.51","value":"5.55"},{"groupId":"OG001","lowerLimit":"5.42","upperLimit":"7.16","value":"5.68"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"431"}],"units":"Participants"}],"description":"PFS is defined as the time from randomization to the first occurrence of PD, as determined by the investigator using RECIST v1.1, or death from any cause during the study, whichever occurs first. PD is defined as greater than or equal to (\\>/=) 20 percent (%) relative increase and \\>/=5 millimeter (mm) of absolute increase in the sum of diameters (SD) of target lesions (TLs), taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive placebo matching to atezolizumab via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo and Paclitaxel"},{"description":"Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m\\^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab and Paclitaxel"}],"paramType":"MEDIAN","populationDescription":"ITT population: all randomized participants, whether or not the assigned study treatment was received","reportingStatus":"POSTED","timeFrame":"From Day 1 to disease progression (PD) or death from any cause, assessed up to primary completion date (approximately 26 months)","title":"Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population","type":"PRIMARY","unitOfMeasure":"Months"}